CU20140046A7 - Derivados de (4- fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio - Google Patents

Derivados de (4- fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio

Info

Publication number
CU20140046A7
CU20140046A7 CU2014000046A CU20140046A CU20140046A7 CU 20140046 A7 CU20140046 A7 CU 20140046A7 CU 2014000046 A CU2014000046 A CU 2014000046A CU 20140046 A CU20140046 A CU 20140046A CU 20140046 A7 CU20140046 A7 CU 20140046A7
Authority
CU
Cuba
Prior art keywords
derivatives
useful
phenylimidazol
ethylamine
sodium channel
Prior art date
Application number
CU2014000046A
Other languages
English (en)
Spanish (es)
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20140046(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CU20140046A7 publication Critical patent/CU20140046A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CU2014000046A 2011-10-26 2014-04-24 Derivados de (4- fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio CU20140046A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (1)

Publication Number Publication Date
CU20140046A7 true CU20140046A7 (es) 2014-10-02

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000046A CU20140046A7 (es) 2011-10-26 2014-04-24 Derivados de (4- fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio

Country Status (28)

Country Link
US (1) US9079878B2 (OSRAM)
EP (1) EP2771335A2 (OSRAM)
JP (1) JP5946538B2 (OSRAM)
KR (1) KR101586966B1 (OSRAM)
CN (1) CN103906746B (OSRAM)
AP (1) AP2014007579A0 (OSRAM)
AU (1) AU2012328034B2 (OSRAM)
BR (1) BR112014009102A2 (OSRAM)
CA (1) CA2850925C (OSRAM)
CL (1) CL2014000956A1 (OSRAM)
CO (1) CO6940427A2 (OSRAM)
CR (1) CR20140185A (OSRAM)
CU (1) CU20140046A7 (OSRAM)
DO (1) DOP2014000085A (OSRAM)
EA (1) EA023375B1 (OSRAM)
EC (1) ECSP14013324A (OSRAM)
GT (1) GT201400079A (OSRAM)
IL (1) IL232267A (OSRAM)
MD (1) MD20140037A2 (OSRAM)
MX (1) MX337469B (OSRAM)
NI (1) NI201400031A (OSRAM)
PE (1) PE20141682A1 (OSRAM)
PH (1) PH12014500919A1 (OSRAM)
SG (1) SG11201401032YA (OSRAM)
TN (1) TN2014000147A1 (OSRAM)
UA (1) UA109220C2 (OSRAM)
WO (1) WO2013061205A2 (OSRAM)
ZA (1) ZA201402281B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6425543B2 (ja) * 2011-09-14 2018-11-21 ダウ アグロサイエンシィズ エルエルシー ボロン酸およびその中間体を生成させるための方法およびシステム
GEP20207082B (en) 2013-12-13 2020-04-10 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
WO2016065341A1 (en) * 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CA3009715A1 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP4650364A3 (en) * 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CN118542952A (zh) 2016-07-06 2024-08-27 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
JP7104070B2 (ja) 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
EP3651752B1 (en) 2017-07-11 2024-11-20 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
UA130303C2 (uk) 2019-12-06 2026-01-14 Вертекс Фармасьютикалз Інкорпорейтед Заміщені тетрагідрофурани як модулятори натрієвих каналів
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4346818B1 (en) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
JP2024522293A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
US20250388541A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
PE20251179A1 (es) 2022-04-22 2025-04-23 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
JP4173191B2 (ja) * 2004-05-07 2008-10-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体
KR20070083828A (ko) 2004-10-27 2007-08-24 쉐링 코포레이션 Ｎａｖ１．８의 짧은 간섭 핵산 억제를 위한 조성물 및방법
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
HRP20110158T1 (hr) 2006-10-18 2011-04-30 Pfizer Products Inc. Biaril eterski spojevi ureje
CA2681572C (en) 2007-03-23 2014-02-11 Icagen, Inc. Inhibitors of ion channels
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
US9079878B2 (en) 2015-07-14
EA023375B1 (ru) 2016-05-31
MX2014004738A (es) 2014-08-01
US20140296313A1 (en) 2014-10-02
DOP2014000085A (es) 2014-08-31
WO2013061205A2 (en) 2013-05-02
MX337469B (es) 2016-03-02
BR112014009102A2 (pt) 2017-04-18
CA2850925C (en) 2017-01-10
GT201400079A (es) 2015-06-02
UA109220C2 (uk) 2015-07-27
CO6940427A2 (es) 2014-05-09
IL232267A0 (en) 2014-06-30
JP5946538B2 (ja) 2016-07-06
CA2850925A1 (en) 2013-05-02
EA201490864A1 (ru) 2014-08-29
AP2014007579A0 (en) 2014-04-30
CN103906746B (zh) 2015-12-09
KR20140069234A (ko) 2014-06-09
KR101586966B1 (ko) 2016-01-19
NZ623090A (en) 2015-10-30
EP2771335A2 (en) 2014-09-03
AU2012328034B2 (en) 2015-04-23
SG11201401032YA (en) 2014-07-30
ZA201402281B (en) 2015-11-25
WO2013061205A8 (en) 2014-03-27
CL2014000956A1 (es) 2014-07-18
AU2012328034A1 (en) 2014-05-15
JP2014530900A (ja) 2014-11-20
IL232267A (en) 2016-10-31
PE20141682A1 (es) 2014-11-14
MD20140037A2 (ro) 2014-08-31
ECSP14013324A (es) 2014-05-31
NI201400031A (es) 2014-10-01
HK1198650A1 (en) 2015-05-22
WO2013061205A3 (en) 2013-06-27
PH12014500919A1 (en) 2014-06-09
CR20140185A (es) 2014-06-03
TN2014000147A1 (fr) 2015-09-30
CN103906746A (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
CU20140046A7 (es) Derivados de (4- fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio
CO2022004594A2 (es) Oxinitruro de piridina, método para su preparación y uso de este
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
CR20200403A (es) Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
MX359882B (es) Amidas como moduladores de canales de sodio.
MX372534B (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201600434A1 (ru) Применение производных бензимидазолпролина
PH12015502632A1 (en) Cxcr7 receptor modulators
MX376307B (es) Derivados de oxazetidina, proceso para su preparacion y uso de los mismos en medicina humana y en cosmetica.
ECSP21037191A (es) Pirazoles como moduladores de la hemoglobina
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
TN2018000175A1 (en) Indane derivatives as mglur7 modulators